JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

MRK

112.26

-1.12%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

MRK

112.26

-1.12%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

MRK

112.26

-1.12%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

MRK

112.26

-1.12%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

MRK

112.26

-1.12%↓

Accueil・Liste d'Actions・Eli Lilly and Co.

Eli Lilly and Co.

Fermé

SecteurSoins de santé

974.96 -1.19

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

965.66

Max

987.92

Chiffres clés
By Trading Economics
Revenu	758M 7.4B
Ventes	507M 20B
P/E Moyenne du Secteur	34.409 49.8
BPA	8.55
Rendement du dividende	0.65
Marge bénéficiaire	37.355
Employés	50,000
EBITDA	971M 9.4B

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+27.94% upside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	0.65% 2.25%
Prochains Résultats	5 août 2026
Date du Prochain Dividende	10 juin 2026
Date du Prochain Détachement de Dividende	15 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	87B 863B
Ouverture précédente	976.15
Clôture précédente	974.96

Sentiment de l'Actualité

By Acuity

33%

67%

94 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

N/A / 884.54 Support & Résistance

Eli Lilly and Co. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 avr. 2026, 12:01 UTC

Résultats

Principaux Mouvements du Marché

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

7 mai 2026, 09:30 UTC

Résultats

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 mai 2026, 12:36 UTC

Résultats

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 mai 2026, 10:12 UTC

Résultats

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 mai 2026, 09:58 UTC

Résultats

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

30 avr. 2026, 20:59 UTC

Actions en Tendance

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30 avr. 2026, 20:12 UTC

Résultats

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 avr. 2026, 16:43 UTC

Résultats

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30 avr. 2026, 16:10 UTC

Market Talk

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30 avr. 2026, 15:13 UTC

Résultats

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 avr. 2026, 14:58 UTC

Résultats

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30 avr. 2026, 14:53 UTC

Résultats

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30 avr. 2026, 14:50 UTC

Résultats

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30 avr. 2026, 14:42 UTC

Résultats

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30 avr. 2026, 14:39 UTC

Résultats

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30 avr. 2026, 14:35 UTC

Résultats

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30 avr. 2026, 14:24 UTC

Résultats

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30 avr. 2026, 14:17 UTC

Résultats

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30 avr. 2026, 13:56 UTC

Résultats

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 avr. 2026, 13:37 UTC

Actions en Tendance

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 avr. 2026, 12:32 UTC

Market Talk

Résultats

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

30 avr. 2026, 12:29 UTC

Market Talk

Résultats

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

30 avr. 2026, 12:23 UTC

Market Talk

Résultats

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

30 avr. 2026, 12:10 UTC

Résultats

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 avr. 2026, 12:08 UTC

Résultats

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

30 avr. 2026, 12:04 UTC

Market Talk

Résultats

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

30 avr. 2026, 11:39 UTC

Actions en Tendance

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 avr. 2026, 11:08 UTC

Résultats

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 avr. 2026, 10:50 UTC

Résultats

Eli Lilly Raises 2026 Performance Margin View to 47%-48.5% From 46%-47.5% >LLY

30 avr. 2026, 10:49 UTC

Résultats

Eli Lilly Had Seen 2026 Revenue $80B-$83B, Adjusted EPS $33.50-$35.00 >LLY

Comparaison

Variation de prix

Eli Lilly and Co. prévision

Objectif de Prix

By TipRanks

27.94% hausse

Prévisions sur 12 Mois

Moyen 1,262.85 USD 27.94%

Haut 1,500 USD

Bas 850 USD

Basé sur 22 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

22 ratings

Achat

Maintien

Vente

Basé sur 22 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

N/A / 884.54Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

94 / 347Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.